Shots: Shots: Boehringer Ingelheim acquires two preclinical programs from Northern Biologic to foster its cancer immunology portfolio in exchange Northern will receive upfront, milestones and other consideration payments. The acquisition will support Boehringer’s strategy to target ‘’cold tumors with synergistic combination approaches” The first program is an Ab inhibitor of Periostin, which contributes to cancer […]Read More
Shots: Seattle to receive upfront plus progress-dependent milestones of up to $160M and royalties on any product sales, retaining rights for candidates in Americas (the US, Canada, and Latin American countries), EU and Japan. BeiGene to get exclusive rights to develop and commercialize the candidates in Asia (Ex- Japan) and ROW and will also be […]Read More
Shots: Novartis to receive up front and up to $291M upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. Gilead acquires exclusive WW rights to develop and commercialize novel small molecules against three undisclosed targets The focus of the agreement is to develop therapies for treat human rhinovirus, […]Read More
Shots: Study involves assessing of inhaled TLR9 agonist with anti-PD-1 in mouse preclinical model, leading a long term survival in two different mouse lung tumour models Administration of SD-101 in lungs of mice with metastatic tumours results in ~90% reduction in tumour burden in lung and liver both enhancing survival time and survival rate of […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
